Commodore Capital LP, along with Commodore Capital Master LP and managing partners Michael Kramarz and Robert Egen Atkinson, filed a Schedule 13G/A on May 15, 2026, disclosing a significant position in Enliven Therapeutics, Inc. (ELVN). As of March 31, 2026, the reporting group beneficially owns 4,800,940 shares of Com...

On May 15, 2026, Biotechnology Value Fund, L.P. (BVF) and its affiliates, including Mark N. Lampert, filed a Schedule 13G/A regarding their holdings in Compass Therapeutics, Inc. (CMPX). As of the event date on March 31, 2026, the reporting group collectively beneficially owns 7,764,842 shares of common stock, represen...

On May 15, 2026, Hood River Capital Management LLC filed a Schedule 13G/A with the SEC, reporting a significant new stake in Comstock Inc. (LODE). As of the event date on March 31, 2026, the investment adviser beneficially owns 6,284,958 shares of common stock, representing 8.48% of the company. This filing marks a sub...

Wei Zheng has filed an amended Schedule 13G/A for Connect Biopharma Holdings Ltd (CNTB), reporting a beneficial ownership of 3,876,036 ordinary shares. This represents a 6.2% stake in the company based on approximately 62.6 million shares outstanding, which includes 56,521,282 shares reported in the issuer's 10-K and a...

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, filed a Schedule 13G/A on May 15, 2026, reporting a 7.06% ownership stake in Contango Silver & Gold Inc. (CTGO). The reporting persons beneficially own a total of 2,267,579 shares of Class A Common Stock as of the event date of March 31, ...

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Context Therapeutics Inc. (CNTX). The filing indicates that the reporting persons collectively hold 2,238,496 shares of common stock, representing a 2.44% ownership stake...

On May 15, 2026, RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, filed an amended Schedule 13G (Amendment No. 2) regarding their holdings in Contineum Therapeutics, Inc. (CTNM). The filing reports that as of March 31, 2026, the reporting persons beneficially own 1,296,012 shares of Class A Com...

On May 15, 2026, Contour Asset Management LLC, along with affiliated entities and principal David L. Meyer, filed a Schedule 13G/A with the SEC regarding their holdings in Zeta Global Holdings Corp. (ZETA). The filing reveals that the reporting group collectively beneficially owns 5,062,355 shares of Common Stock, repr...

On May 15, 2026, Silver Point Capital, L.P., along with Edward A. Mule and Robert J. O'Shea, filed Amendment No. 1 to their Schedule 13G regarding Cool Company Ltd. (CLCO). This filing serves as an official 'exit filing' for the reporting persons, indicating that they have reduced their beneficial ownership to zero sha...

Millstreet Capital Management LLC, along with principals Brian D. Connolly and Craig M. Kelleher, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Cooper-Standard Holdings Inc. (CPS). The filing serves as Amendment No. 1 and reports an event date of March 31, 2026. According to the document, the repo...

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, disclosing a significant stake in CorMedix Inc. (CRMD). As of the event date on March 31, 2026, the reporting persons collectively hold 6,274,076 shares of common stock, representing a ...

Disciplined Growth Investors, Inc. filed a Schedule 13G/A on May 15, 2026, disclosing a significant increase in its stake in Core Laboratories Inc. (CLB). As of the event date of March 31, 2026, the Minneapolis-based investment adviser reported beneficial ownership of 4,937,115 common shares, representing 10.7% of the ...

Valiant Capital Management, L.P., Valiant Capital Management, LLC, and Christopher R. Hansen have filed a joint Schedule 13G/A reporting a significant increase in their position in Core Scientific, Inc. (CORZ). As of the event date on March 31, 2026, the reporting persons collectively hold 16,213,103 shares of Common S...

Citadel Securities GP LLC, along with Kenneth Griffin and associated entities, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Core Scientific, Inc. (CORZ). The filing reveals that Citadel Securities GP LLC, Citadel Securities Group LP, and Kenneth Griffin are deemed to beneficially own 12,792,480 s...

Susquehanna Securities, LLC, along with affiliated entities G1 Execution Services, LLC, SIG Brokerage, LP, and Susquehanna Investment Group, filed a Schedule 13G/A on May 15, 2026, disclosing a collective beneficial ownership of 14,631,891 shares of Core Scientific, Inc. (CORZ). This position represents approximately 4...

Cooper Creek Partners Management LLC filed a Schedule 13G/A on May 15, 2026, disclosing a position in CoreCivic, Inc. (CXW). According to the filing, the investment manager beneficially owns 2,849,459 shares of common stock, representing a 2.7% ownership stake in the company. This filing serves as an amendment to a pre...

This Schedule 13G/A filing, dated May 15, 2026, reports an aggregate beneficial ownership of 7.6% of CoreWeave, Inc. Class A common stock by a group of reporting persons led by Brian M. Venturo. The group collectively owns 34,327,941 shares. Brian M. Venturo directly and indirectly controls 28,032,541 shares (6.2%), in...

This Schedule 13G/A filing, dated May 15, 2026, indicates that Cormorant Asset Management, LP and Bihua Chen have fully exited their position in enGene Holdings Inc. (ENGN). As of the event date on March 31, 2026, the reporting persons reported owning 0 shares of common stock, representing 0% of the company's outstandi...

On May 15, 2026, Cormorant Asset Management, LP and Bihua Chen filed a Schedule 13G/A for iBio, Inc. (IBIO), reporting a beneficial ownership of 3,834,335 shares of Common Stock. This position represents a 9.99% ownership stake in the company, a significant increase from the 0.0% previously reported. The reported holdi...

Cormorant Asset Management, LP, along with its managing member Bihua Chen, has filed a Schedule 13G/A indicating a significant increase in their position in MoonLake Immunotherapeutics (MLTX). As of March 31, 2026, the reporting persons beneficially own 4,480,433 Class A ordinary shares, representing a 6.25% stake in t...

Cormorant Asset Management, LP, and its managing member, Bihua Chen, have filed a Schedule 13G/A regarding their holdings in Rapport Therapeutics, Inc. (RAPP). As of the event date on March 31, 2026, the reporting persons disclosed a beneficial ownership of 2,957,521 shares of Common Stock, representing 6.19% of the co...

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have filed a Schedule 13G/A with the SEC, reporting that they have fully exited their position in Corvus Pharmaceuticals, Inc. (CRVS) as of March 31, 2026. This amendment (Amendment No. 1) indicates that the reporting persons no longer ...

Wellington Management Group LLP, along with its affiliated entities Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Coterra Energy Inc. (CTRA). The filing indicates that as of March 31,...

Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Crane NXT, Co. (CXT). The filing reports a beneficial ownership of 814,164 shares of common stock, representing 1....

T. Rowe Price Associates, Inc. filed a Schedule 13G/A on May 15, 2026, disclosing a 5.1% stake in Crinetics Pharmaceuticals, Inc. (CRNX). As of the event date on March 31, 2026, the investment firm reported beneficial ownership of 5,355,011 shares of common stock. This filing represents an increase from a previously re...